Pharma Globenewswire - Page 52 of 429 - Press Release And News Distribution

Suggestions

Press Release And News Distribution

News
Drug Launches & Approvals
Clinical Trials
Market Insights
Artificial Intelligence
Commercial
More

Latest

Search

Recent Posts

Menkes Disease Market Set to Grow Through 2036 as First Approved Therapy Establishes Standard of Care and Gene Therapy Advances Preclinically
GABA Inhibitor Market Poised for Transformation Through 2034 Amid Expanding Therapeutic Opportunities
Gene Therapy Market Forecast 2032: Rising Demand, Novel Therapies, and Commercial Potential – DelveInsight
Treatment-Resistant Depression Market Forecast 2036: Rising Demand, Novel Therapies, and Commercial Potential – DelveInsight
Erectile Dysfunction Market Expected to Witness Significant Growth by 2034, Driven by Therapeutic Innovation and Rising Awareness DelveInsight

Banner

Newsletter

Authors

pharmaglobenews

Menkes Disease Market Set to Grow Through 2036 as First Approved Therapy Establishes Standard of Care and Gene Therapy Advances Preclinically
Michael Ashford

Motor Neuron Disease Pipeline Insight 2026: Driving Hope Through Next-Generation Therapies

© 2026 - ALL RIGHTS RESERVED.
Pharma GlobeNewswire is a specialized press release distribution platform focused on the pharmaceutical, biotechnology, and healthcare sectors. It enables companies to share news related to drug development, clinical trials, regulatory updates, market insights, and corporate announcements with a global audience. By leveraging targeted distribution channels, Pharma GlobeNewswire helps organizations enhance visibility, reach industry stakeholders, and amplify their brand presence within the life sciences ecosystem.

About
Privacy
Help
Terms
Contact

Popular

NCFB Market on the Brink of Change as First DPP1 Inhibitor Marks Approval | DelveInsight

The NCFB market is entering a new phase as Insmed’s

News
Drug Launches & Approvals
Clinical Trials
Market Insights
Artificial Intelligence
Commercial
More